Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095517 · ClinicalTrials.gov registry record · Phase 1
Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
A Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07095517 is a Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 1,428-participant average among 8 other Colorectal Adenoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07095517, a Phase 1 study of Colorectal Adenoma and Colorectal Cancer Prevention, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial approach for a future larger study.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07095517
The ClinicalTrials.gov registry entry for NCT07095517 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,428-participant average among 8 other Colorectal Adenoma trials with a reported enrollment target (99% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Adenoma appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT07095517 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07095517 about?
NCT07095517 is a clinical study titled "Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors". This research study is an open-label Phase 1 Exploratory/Pilot clinical trial to measure the effects of the incretin mimetic, tirzepatide, on tissue, urine, blood, and microbiome biomarkers associated with colorectal cancer risk and to understand the feasibility of this precision prevention trial ap...
What is the current status of trial NCT07095517?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-02-24. Estimated completion is 2028-12-31.
What conditions does trial NCT07095517 study?
This clinical trial studies the following conditions: Colorectal Adenoma, Colorectal Cancer Prevention.
What interventions are being tested in trial NCT07095517?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT07095517?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095517 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Gixam's Performance in a FIT Negative Population
RECRUITING · Phase 2
-
PARADIGM - En Bloc Trial With the EndoQuest Endoluminal Surgical (ELS) System
RECRUITING · NA
-
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
RECRUITING · NA
-
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
ACTIVE NOT RECRUITING · Phase 2
-
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
ACTIVE NOT RECRUITING · Phase 2
-
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.